Inside informationEnglish
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Valneva SE
- Filed
- 04/11/2025, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 116691_20251104